Ondansetron Accordpharma

Ondansetron, the active ingredient in Ondansetron Accordpharma, is a 5-HT3 receptor antagonist presented as a unknown/unknown for unknown use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative recovery in adults and children. GNH USA supplies Ondansetron Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used in the prevention and treatment of nausea and vomiting across several clinical pathways.

- Chemotherapy‑induced nausea and vomiting: Reduces the frequency and severity of nausea and vomiting caused by cytotoxic chemotherapy. - Radiation‑induced nausea and vomiting: Helps mitigate the nausea and vomiting that can follow radiation therapy. - Post‑operative nausea and vomiting: Decreases the incidence of post‑surgical nausea and vomiting. - Pregnancy‑related nausea: Provides symptomatic relief for nausea associated with early pregnancy, when prescribed by a physician.

Common Side Effects: - Headache: mild to moderate headache may occur. - Constipation: reduced bowel movements are reported. - Diarrhoea: occasional loose stools. - Fatigue: feeling of tiredness or low energy. - Dizziness: transient light‑headedness. - Injection site pain: mild discomfort if administered parenterally.

Serious or Rare Side Effects: - QT prolongation: may affect cardiac rhythm. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare but potentially life‑threatening when combined with other serotonergic drugs. - Hepatic dysfunction: elevated liver enzymes. - Neuroleptic malignant syndrome‑like picture: rare neuromuscular disturbances. - Cardiac arrhythmia: irregular heartbeat beyond QT changes.

Ondansetron should be used with caution in patients with known cardiac conduction abnormalities.

- Cardiac monitoring: perform ECG monitoring in patients at risk for QT prolongation. - Electrolyte balance: correct hypokalemia, hypomagnesemia, or hypocalcaemia before use. - Drug interactions: review the list of concomitant medications for potential interactions. - Pregnancy: assess the risk‑to‑benefit ratio when prescribing to pregnant women. - Breastfeeding: consider the potential exposure to the infant through milk. - Store at below 25°C: keep the product in the original pack by to the by the ...

The    ...  ... ...  ... ... ....  t  ....  t ... 

"""""  "  " """ "" "  "" ""  "" "  "" " " "" "" "" " "" "  "  "" " "" "" " " "  "" " " "